Tirzepatide Improves Sleep Quality, Daytime Function, and Quality of Life in People With Sleep Apnea and Obesity | Research

The takeaway

In the Phase 3 SURMOUNT-OSA trials, tirzepatide significantly improved patient-reported sleep quality, daytime functioning, sleepiness, and overall quality of life compared to placebo over 52 weeks in people with moderate-to-severe sleep apnea and obesity.

All PROMs significantly improved
Tirzepatide improved every patient-reported sleep, functioning, and quality of life measure at 52 weeks compared to placebo in the SURMOUNT-OSA Phase 3 trials

What the researchers found

At 52 weeks, tirzepatide (10 or 15 mg) produced significantly greater improvements compared to placebo across multiple patient-reported outcome measures: PROMIS Sleep-Related Impairment, PROMIS Sleep Disturbance, Functional Outcomes of Sleep Questionnaire activity levels, EQ-5D-5L quality of life, and most domains of the SF-36 health survey.

Tirzepatide was also associated with greater improvements on the Patient Global Impression of Status and Change scales. In Study 1 (participants not using PAP therapy), Epworth Sleepiness Scale scores (daytime sleepiness) also improved significantly. These subjective benefits complement the previously reported objective improvements in AHI (breathing interruption frequency), hypoxic burden, and cardiovascular risk factors.

Why it matters

Sleep apnea affects an estimated 936 million adults worldwide, and the standard treatment — CPAP machines — has notoriously poor adherence. Tirzepatide could become the first effective pharmaceutical alternative for sleep apnea, and these patient-reported data show that the benefits extend beyond laboratory measurements to real improvements in how patients sleep, function, and feel. This makes a compelling case for a new treatment paradigm.

How the study worked

Prespecified analysis of patient-reported outcomes from SURMOUNT-OSA — two randomized, double-blind, placebo-controlled Phase 3 trials of tirzepatide (10 or 15 mg) for 52 weeks in participants with moderate-to-severe OSA and obesity. Study 1 enrolled patients not using PAP; Study 2 enrolled PAP users who withdrew PAP before assessments. Multiple validated PROMs were assessed at baseline and Week 52 using analysis of covariance.

What this study cannot tell us

This is a secondary analysis of prespecified endpoints from the SURMOUNT-OSA trials — the primary endpoint (AHI reduction) was reported separately. In Study 2, PAP was withdrawn before assessment, which may have influenced results. Patient-reported outcomes are inherently subjective. The 52-week duration, while substantial, doesn't address long-term durability of benefits. The study population may not represent all sleep apnea patients.

How to read the evidence

This is a prespecified secondary analysis from Phase 3 randomized, double-blind, placebo-controlled trials — the highest quality of clinical evidence. The use of multiple validated patient-reported outcome measures strengthens confidence in the findings.

When this study was published

Published in 2025, this represents the latest data from the landmark SURMOUNT-OSA program that is supporting tirzepatide's potential approval for obstructive sleep apnea — a new indication for this drug class.

The bigger picture

Tirzepatide's approval for sleep apnea would mark a paradigm shift — treating a mechanical breathing disorder with a metabolic peptide drug. The SURMOUNT-OSA results demonstrate that addressing the underlying obesity that drives sleep apnea can produce improvements across the full spectrum of disease burden: objective breathing measures, cardiovascular risk, and now subjective quality of life. This aligns with the broader trend of GLP-1-based drugs treating the systemic consequences of obesity, not just the weight itself.

Questions still open

Do the sleep quality and functional improvements persist with continued tirzepatide treatment beyond 52 weeks?
Could tirzepatide eventually replace CPAP therapy for some patients with obesity-related sleep apnea?
Are the quality of life improvements driven primarily by weight loss, sleep apnea improvement, or both independently?

Common questions

How does a weight loss drug help with sleep apnea?

In obstructive sleep apnea, excess fat tissue around the throat and in the abdomen puts pressure on the airway, causing it to collapse repeatedly during sleep. By reducing body weight, tirzepatide reduces this physical pressure, keeping the airway more open. This study showed that patients not only had fewer breathing interruptions (measured objectively) but also felt the difference — sleeping better, feeling less tired during the day, and functioning better overall.

Could tirzepatide replace CPAP machines for sleep apnea?

Possibly for some patients. CPAP is effective when used, but many people can't tolerate wearing a mask every night. The SURMOUNT-OSA trials showed that tirzepatide produced meaningful improvements in sleep apnea severity and patient-reported quality of life through a weekly injection instead. For patients with obesity-related sleep apnea who struggle with CPAP, this could be a game-changing alternative — though whether it fully replaces CPAP or serves as a complement depends on individual cases.

Read the original research

Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.

Sleep medicine, 134, 106719

View on PubMed ↗Publisher’s paper ↗

Citation

Kanu, Chisom; Shinde, Shraddha; Chakladar, Sujatro; Dennehy, Ellen B; Weaver, Terri E; Poon, Jiat Ling; Malhotra, Atul. (2025). Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.. Sleep medicine, 134, 106719. https://doi.org/10.1016/j.sleep.2025.106719